August 2026 FDA Approvals: 7 New Drugs Creating Future Market Opportunities

• The CEO of Helus Pharma will participate in a live webcast on September 14 during the H.C. Wainwright conference in New York. • The presentation begins at 9 a.m. EDT and will be available for replay on the company's Events & Presentations page.

• NanoViricides, Inc. registered a successful Phase II clinical trial for its NV-387 oral gummies designed to treat Ebola viruses in the Democratic Republic of the Congo. • Professor Patrick de Marie Chimusa Katoto led the trial and expects dosing to begin within one to two weeks.

• NanoViricides announced on September 8, 2026, that it has registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo. • The company reports that NV-387 previously performed better than the drug Remdesivir in a lethal animal model of a viral disease.

• NanoViricides announced on September 8, 2026, that it registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo Ebola virus. • The trial is listed in the Pan African Clinical Trials Database to address the expanding Ebola outbreak in the Democratic Republic of Congo.

• New artificial intelligence tools including specialized large language models and AI-assisted CT scans are being integrated into oncology care to improve early detection and pathology. • ChatGPT Health now allows patients to connect medical records and wellness apps to their AI experience to assist with health-related decisions.

• NanoViricides, Inc. registered a successful Phase II clinical trial for its NV-387 oral gummies designed to treat Ebola viruses in the Democratic Republic of the Congo. • Professor Patrick de Marie Chimusa Katoto led the trial and expects dosing to begin within one to two weeks.

• Superluminal and AusperBio secured venture capital funding in early 2026. • Superluminal raised $60 million while AusperBio added $120 million to its funding.

• Pharmaceutical companies are rebounding as clarity emerges regarding U.S. drug pricing regulations. • Diversified firms like Johnson & Johnson (JNJ) and AstraZeneca (AZN) are utilizing strong research and development pipelines to offset looming patent cliffs, which occur when exclusive rights to a drug expire.

• The FDA approved Rasonque, a new pancreatic cancer drug developed by Revolution Medicines. • Patients seeking the treatment have found that insurance coverage can take several weeks to catch up with the official approval.

• European biomedical innovation is declining as clinical trials and investment shift toward other global regions. • The region previously led the world in pharmaceutical research and delivered medical advances that transformed millions of lives.

• The FDA recently approved the intravenous antibiotic fosfomycin, marketed as Contepo, for adults with complicated urinary tract infections. • This medication targets infections caused by resistant Gram-negative pathogens, which are bacteria that resist common antibiotic treatments.